WASHINGTON, May 27 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to Sato Pharmaceutical Co. Ltd. from its Center for Drug Evaluation and Research:

* * *

Recipient: Seiichi Sato, President and CEO, Sato Pharmaceutical Co., Ltd., 1-5-27 Moto-Akasaka Minato-ku, Tokyo 107-0051, Japan, seiichi@sato-seiyaku.co.jp

Issuing Office: Center for Drug Evaluation and Research (CDER), United States